We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Four Years Later, Merck KGaA Takes Another Stab at Approval for MS Drug
Four Years Later, Merck KGaA Takes Another Stab at Approval for MS Drug
Merck KGaA has informed the European Medicines Agency that it will apply for marketing authorization for its multiple sclerosis drug Cladribine, four years after the firm withdrew its application following a negative opinion from the Committee for Medicinal Products for Human Use.